RARITAN, N.J., Nov. 9, 2015 /PRNewswire/ — Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies including HM12525A, a biologic that is completing Phase 1 and expected to enter Phase 2 studies next year, from Hanmi Pharmaceutical Co., Ltd. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
HM12525A is an oxyntomodulin-based therapy (GLP-1/glucagon receptor dual agonist) that has shown evidence of improving multiple metabolic parameters that lead to improved blood glucose, body weight, and insulin sensitivity. This asset has the potential, as a once weekly therapy, to be a best-in-class oxyntomodulin-based therapy.
“We are very excited about this agreement with Hanmi and the potential of HM12525A to improve therapeutic options for people living with metabolic diseases,” said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen. “Our deep scientific expertise and demonstrated clinical development capabilities support our commitment to aggressively develop and launch transformational therapies for patients with cardiovascular and metabolic diseases. We look forward to developing this potential best-in-class therapy, which allows us to build on our success in diabetes and strengthen our metabolism portfolio.”
About the Janssen Pharmaceutical Companies of Johnson & Johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including cardiovascular and metabolic diseases (e.g., diabetes and thrombosis), immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), neuroscience (e.g., schizophrenia, dementia and pain) and oncology (e.g., multiple myeloma and prostate cancer).
Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. To learn more, visit www.janssen.com.
Source: Janssen Pharmaceuticals, Inc.